IP Library Granted Patent US 8,980,936
Granted Patent B2
US 8,980,936 · App. 13/945,622 · Granted Mar 17, 2015

Phenoxy-pyrrolidine derivative and its use and compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,980,936
App. No.
13/945,622
Granted
Mar 17, 2015
Kind
B2
Abstract

The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound.

Claims (20)

1. A method of increasing energy expenditure in a subject in need thereof comprising administering to the subject a compound of Formula I

or a pharmaceutically acceptable salt, solvate or hydrate thereof, in an amount effective to increase the subject's energy expenditure.

2. The method of claim 1 , wherein the subject is a human.

3. The method of claim 1 , wherein the compound is administered topically, orally or parenterally.

4. A method of treating diabetes or increasing insulin sensitivity in subject in need thereof, comprising administering to the subject a compound of Formula I

or a pharmaceutically acceptable salt, solvate or hydrate thereof, in an amount effective to treat the subject's diabetes or increase the subject's insulin sensitivity.

5. The method of claim 4 , wherein the subject is a human.

6. The method of claim 4 , wherein the compound is administered topically, orally or parenterally.

7. A method of treating cancer in a subject in need thereof, comprising administering to the subject a compound of Formula I

or a pharmaceutically acceptable salt, solvate or hydrate thereof, in an amount effective to treat the subject's cancer.

8. The method of claim 7 , wherein the subject is a human.

9. The method of claim 7 , wherein the compound is administered topically, orally or parenterally.

10. A method of reducing the size and number of sebaceous glands in a subject, comprising administering to the subject a compound of Formula I

or a pharmaceutically acceptable salt, solvate or hydrate thereof, in an amount effective to reduce the size and number of the subject's sebaceous glands.

11. The method of claim 10 , wherein the subject is a human.

12. The method of claim 10 , wherein the compound is administered topically, orally or parenterally.

13. A method of treating Propionibacterium acnes growth by reducing sebum production and secretion in a subject in need thereof, comprising administering to the subject a compound of Formula I

or a pharmaceutically acceptable salt, solvate or hydrate thereof, in an amount effective to treat Propionibacterium acnes growth by reducing the subject's sebum production and secretion.

14. The method of claim 13 , wherein the subject is a human.

15. The method of claim 13 , wherein the compound is administered topically, orally or parenterally.

Assignments (7)
CHANGE OF NAME Recorded Oct 27, 2020
From: GDD THERAPEUTICS, INC.
To: LIPIDIO PHARMACEUTICALS INC.
Reel/Frame 054226/0049 →
MERGER AND CHANGE OF NAME Recorded Oct 26, 2020
From: GDD THERAPEUTICS, LLC; GDD THERAPEUTICS, INC.
To: GDD THERAPEUTICS, INC.
Reel/Frame 054209/0327 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2018
From: THESAN PHARMACEUTICALS, INC.
To: GDD THERAPEUTICS, LLC
Reel/Frame 046687/0622 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2014
From: KOLOSKO, NICOLE L.; LI, JIN
To: PFIZER INC.
Reel/Frame 031944/0321 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2014
From: GRACEWAY PHARMACEUTICALS, LLC
To: MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 031944/0256 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2014
From: PFIZER INC.
To: GRACEWAY PHARMACEUTICALS, LLC
Reel/Frame 031944/0308 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2013
From: MEDICIS PHARMACEUTICAL CORPORATION
To: THESAN PHARMACEUTICALS, INC.
Reel/Frame 031280/0766 →